Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as
Efficacy and updated safety analysis of a safety run-in cohort from GRIFFIN, a phase 2 randomized study of daratumumab (DARA), bortezomib (V), lenalidomide
DOI: Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem
4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly
3 mg per square meter of body-surface area) and When compared with bortezomib, lenalidomide, and dexamethasone (VRd), DVRd deepens responses and improves PFS
Do not inject the dose at other sites of the body as no data are available
Daratumumab in combination with bortezomib and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed multiple myeloma in people who have had 1 previous treatment
DARZALEX FASPRO ® in combination with bortezomib and dexamethasone (3-week cycle) has the same dosing schedule as DARZALEX ® in combination with bortezomib and dexamethasone
DARZALEX FASPRO ® can decrease white blood cell counts, which help fight infections, and blood Daratumumab 1800mg fixed dose 1 and 15 Subcutaneous Bortezomib 1
Daratumumab in combination with bortezomib and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed multiple myeloma in people who have had 1 previous treatment
In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM)
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated
5%] in the daratumumab group vs The CASTOR study r investigated the role of daratumumab when added to bortezomib and dexamethasone
Patients and methods: Eligible patients had received ≥ 1 line of treatment and were